4th International AIDS Society Conference on HIV Pathogenesis and Treatment


Sydney, Australia - July 22 - 25, 2007

EFFECT OF HIV-1 INFECTION AND INCREASING IMMUNOSUPPRESSION ON MENSTRUAL FUNCTION

IAS Conf HIV Pathog Treat 2007 Jul 22-25;4th: Abstract No. MOPDB02

Ezechi O.C.1, Jogo A.2, Njemanze O.1, Gab-Okafor C.1, Onwujekwe D.1, Odunukwe N.1, Ezeobi P.1, Gbajabiamila T.1, Adu R.1, Audu R.3, Akinbami O.1, Somefun E.1, Musa A.1, Salu O.3, Meshack E.3, Anyanwu R.1, Amadi E.1, Nwogbe O.1, Ekong E.4, Idigbe O.5, Kanki P.4
1Nigerian Institute of Medical Research, Clinical Sciences Division, Lagos, Nigeria, 2Federal Medical Centre, Markurdi, Nigeria, 3Nigerian Institute of Medical Research, Human Virology Laboratory, Lagos, Nigeria, 4AIDS Prevention Initiative in Nigeria Plus, Lagos, Nigeria, 5Nigerian Institute of Medical Research, Lagos, Nigeria

OBJECTIVES: To determine the effect of HIV-1 infection, advancing immunosuppression and HAART on the menstrual function of Nigerian women.

METHODS: A cross-sectional study of 627 HIV-1 positive and 651 HIV negative consecutive and consenting women aged 18-40 years seen at the VCT and ARV centres of 2 tertiary HIV treatment centres in Nigeria. Information was obtained on sociodemographic characteristics and menstrual function in the preceeding 6 months using a structured questionnaire designed for the study. Also obtained were anthropometric measurements, CD4 and viral load values. Data entry and analysis was with SPSS for windows Version 10.

RESULTS: Menstrual dysfunction was significantly commoner in PLWHAs (28.4%) than in their HIV negative (14.8%) women (P=0.000). The proportions of women in the two groups with intermenstrual bleeding, menorrhagia, hypomenorrhoea, and postcoital bleeding were similar (p>0.005), however amenorrhea, oligomenorrhoea, irregular periods and secondary dysmenorrhoea were commoner in the HIV positive women (p<0.02). Primary dysmenorrhoea was less common in HIV positives (P<0.03). Among the HIV positives, menstrual dysfunctions were commoner in PLWHAs with OIs, CD4 count less than 200, not on therapy, symptomatic disease and BMI <20, however after controlling for cofounder only CD4 <200 (OR: 3.65; CI: 1.18-6.7), BMI < 20 (OR: 2.1; CI: 1.2-3.2) and not on ARV drugs (OR: 1.9; CI: 1.47-7.7) were associated with menstrual abnormalities of amenorrhea, oligomenorrhoea, irregular periods and secondary dysmenorrhoea.

CONCLUSIONS: HIV-1 infection is associated with an increased frequency of menstrual abnormalities. This association tends to become more pronounced with advancing immunosuppression, weight loss and improves with ARV drug use.

Power Point PresentationDownload Power Point Presentation.

2007-07-22
MOPDB02
Pathogenesis and Treatment in Women

Copyright © 2007 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.